Real Time Insider Transaction Data
Real Time Insider buys and sells Data - Insider Trades - Insider Transactions - Insider Trading Data - SEC Form 4 Data
Total | Transactions | Amount |
Buys | 0 | $0 |
Sells | 69 | $37,510,389 |
Security | Reporting Name | Relationship | Purchase/Sale | Shares | Price $ | D/I | ||||
05 Aug 2024 16:25 | NVCR | NovoCure Ltd | CORDOVA ASHLEY | Chief Financial Officer | 02 Aug 2024 | Sale | 688 | 20.1416 | 13,857 | D |
06 Jun 2024 17:43 | NVCR | NovoCure Ltd | VERNON W ANTHONY | Director | 04 Jun 2024 | Sale | 964 | 23.893 | 23,033 | D |
06 Jun 2024 17:42 | NVCR | NovoCure Ltd | SCANNELL TIMOTHY J | Director | 04 Jun 2024 | Sale | 964 | 23.8874 | 23,027 | D |
06 Jun 2024 17:42 | NVCR | NovoCure Ltd | LEUNG GABRIEL | Director | 04 Jun 2024 | Sale | 964 | 23.8851 | 23,025 | D |
05 Mar 2024 16:09 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Officer | 04 Mar 2024 | Sale | 1,217 | 16.01 | 19,484 | D |
05 Mar 2024 16:09 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Officer | 01 Mar 2024 | Sale | 2,107 | 16.0269 | 33,769 | D |
05 Mar 2024 16:08 | NVCR | NovoCure Ltd | LEONARD FRANK X | EVP, Pres., Novocure Oncology | 04 Mar 2024 | Sale | 840 | 16.01 | 13,448 | D |
05 Mar 2024 16:08 | NVCR | NovoCure Ltd | LEONARD FRANK X | EVP, Pres., Novocure Oncology | 01 Mar 2024 | Sale | 1,679 | 16.0269 | 26,909 | D |
29 Feb 2024 16:38 | NVCR | NovoCure Ltd | LEONARD FRANK X | EVP, Pres., Novocure Oncology | 28 Feb 2024 | Sale | 2,078 | 16.1428 | 33,545 | D |
29 Feb 2024 16:28 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Officer | 28 Feb 2024 | Sale | 2,303 | 16.1428 | 37,177 | D |
08 Nov 2023 16:22 | NVCR | NovoCure Ltd | SHAH PRITESH | Chief Growth Officer | 07 Nov 2023 | Sale | 382 | 12.65 | 4,832 | D |
05 Sep 2023 16:24 | NVCR | NovoCure Ltd | CORDOVA ASHLEY | Chief Financial Officer | 01 Sep 2023 | Sale | 883 | 21.8172 | 19,265 | D |
05 Sep 2023 16:24 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Officer | 01 Sep 2023 | Sale | 294 | 21.8172 | 6,414 | D |
05 Sep 2023 16:23 | NVCR | NovoCure Ltd | SHAH PRITESH | Chief Growth Officer | 01 Sep 2023 | Sale | 273 | 21.8172 | 5,956 | D |
04 Aug 2023 16:02 | NVCR | NovoCure Ltd | CORDOVA ASHLEY | Chief Financial Officer | 02 Aug 2023 | Sale | 1,144 | 30.2511 | 34,607 | D |
07 Mar 2023 16:52 | NVCR | NovoCure Ltd | LEONARD FRANK X | President, CNS Cancers US | 07 Mar 2023 | Sale | 2,315 | 75.5937 | 174,999 | D |
07 Mar 2023 16:52 | NVCR | NovoCure Ltd | LEONARD FRANK X | President, CNS Cancers US | 07 Mar 2023 | Sale | 6,003 | 74.9968 | 450,206 | D |
07 Mar 2023 16:52 | NVCR | NovoCure Ltd | LEONARD FRANK X | President, CNS Cancers US | 03 Mar 2023 | Sale | 888 | 76.1594 | 67,630 | D |
07 Mar 2023 16:52 | NVCR | NovoCure Ltd | LEONARD FRANK X | President, CNS Cancers US | 03 Mar 2023 | Sale | 4,403 | 76.1594 | 335,330 | D |
07 Mar 2023 16:52 | NVCR | NovoCure Ltd | SHAH PRITESH | Chief Growth Officer | 03 Mar 2023 | Sale | 16,909 | 76.1594 | 1,287,779 | D |
07 Mar 2023 16:52 | NVCR | NovoCure Ltd | SHAH PRITESH | Chief Growth Officer | 03 Mar 2023 | Sale | 2,942 | 76.1594 | 224,061 | D |
07 Mar 2023 16:52 | NVCR | NovoCure Ltd | SHAH PRITESH | Chief Growth Officer | 03 Mar 2023 | Sale | 1,570 | 76.1594 | 119,570 | D |
07 Mar 2023 16:51 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Officer | 03 Mar 2023 | Sale | 20,415 | 76.1594 | 1,554,794 | D |
07 Mar 2023 16:51 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Officer | 03 Mar 2023 | Sale | 1,692 | 76.1594 | 128,862 | D |
07 Mar 2023 16:51 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Officer | 03 Mar 2023 | Sale | 3,528 | 76.1594 | 268,690 | D |
07 Mar 2023 16:51 | NVCR | NovoCure Ltd | CORDOVA ASHLEY | Chief Financial Officer | 03 Mar 2023 | Sale | 775 | 76.1594 | 59,024 | D |
07 Mar 2023 16:51 | NVCR | NovoCure Ltd | CORDOVA ASHLEY | Chief Financial Officer | 03 Mar 2023 | Sale | 4,730 | 76.1594 | 360,234 | D |
07 Mar 2023 16:50 | NVCR | NovoCure Ltd | BURKE WILLIAM PATRICK | Chief Human Resources Officer | 03 Mar 2023 | Sale | 593 | 76.1594 | 45,163 | D |
06 Mar 2023 16:42 | NVCR | NovoCure Ltd | BURKE WILLIAM PATRICK | Chief Human Resources Officer | 02 Mar 2023 | Sale | 281 | 75.2779 | 21,153 | D |
06 Mar 2023 16:41 | NVCR | NovoCure Ltd | SHAH PRITESH | Chief Growth Officer | 02 Mar 2023 | Sale | 937 | 75.2779 | 70,535 | D |
06 Mar 2023 16:40 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Officer | 02 Mar 2023 | Sale | 1,213 | 75.2779 | 91,312 | D |
06 Mar 2023 16:40 | NVCR | NovoCure Ltd | CORDOVA ASHLEY | Chief Financial Officer | 02 Mar 2023 | Sale | 1,055 | 75.2779 | 79,418 | D |
06 Mar 2023 16:37 | NVCR | NovoCure Ltd | LEONARD FRANK X | President, CNS Cancers US | 03 Mar 2023 | Sale | 2,059 | 77.6391 | 159,859 | D |
06 Mar 2023 16:37 | NVCR | NovoCure Ltd | LEONARD FRANK X | President, CNS Cancers US | 02 Mar 2023 | Sale | 844 | 75.2779 | 63,535 | D |
03 Mar 2023 16:13 | NVCR | NovoCure Ltd | LEONARD FRANK X | President, CNS Cancers US | 02 Mar 2023 | Sale | 308 | 76.0511 | 23,424 | D |
03 Mar 2023 16:13 | NVCR | NovoCure Ltd | LEONARD FRANK X | President, CNS Cancers US | 02 Mar 2023 | Sale | 3,799 | 75.3235 | 286,154 | D |
02 Mar 2023 17:01 | NVCR | NovoCure Ltd | LEONARD FRANK X | President, CNS Cancers US | 01 Mar 2023 | Sale | 1,684 | 76.3624 | 128,594 | D |
02 Mar 2023 17:00 | NVCR | NovoCure Ltd | SHAH PRITESH | Chief Growth Officer | 01 Mar 2023 | Sale | 1,923 | 76.3624 | 146,845 | D |
02 Mar 2023 16:55 | NVCR | NovoCure Ltd | CORDOVA ASHLEY | Chief Financial Officer | 01 Mar 2023 | Sale | 2,198 | 76.3624 | 167,845 | D |
02 Mar 2023 16:51 | NVCR | NovoCure Ltd | BURKE WILLIAM PATRICK | Chief Human Resources Officer | 01 Mar 2023 | Sale | 755 | 76.3624 | 57,654 | D |
02 Mar 2023 16:49 | NVCR | NovoCure Ltd | GROENHUYSEN WILHELMUS CM | Chief Operating Officer | 01 Mar 2023 | Sale | 2,164 | 76.3624 | 165,248 | D |
09 Jan 2023 18:24 | NVCR | NovoCure Ltd | WEINBERG URI | Chief Science Officer | 05 Jan 2023 | Sale | 1,201 | 120 | 144,120 | D |
09 Jan 2023 18:24 | NVCR | NovoCure Ltd | WEINBERG URI | Chief Science Officer | 05 Jan 2023 | Sale | 2,617 | 108 | 282,636 | D |
09 Jan 2023 18:24 | NVCR | NovoCure Ltd | WEINBERG URI | Chief Science Officer | 05 Jan 2023 | Sale | 1,946 | 120 | 233,520 | D |
09 Jan 2023 18:24 | NVCR | NovoCure Ltd | WEINBERG URI | Chief Science Officer | 05 Jan 2023 | Sale | 2,379 | 120 | 285,480 | D |
09 Jan 2023 18:21 | NVCR | NovoCure Ltd | LEONARD FRANK X | President, CNS Cancers US | 05 Jan 2023 | Sale | 7,183 | 120 | 861,960 | D |
09 Jan 2023 18:21 | NVCR | NovoCure Ltd | LEONARD FRANK X | President, CNS Cancers US | 05 Jan 2023 | Sale | 7,183 | 114.0001 | 818,863 | D |
09 Jan 2023 18:21 | NVCR | NovoCure Ltd | LEONARD FRANK X | President, CNS Cancers US | 05 Jan 2023 | Sale | 5,517 | 108 | 595,836 | D |
09 Jan 2023 18:21 | NVCR | NovoCure Ltd | LEONARD FRANK X | President, CNS Cancers US | 05 Jan 2023 | Sale | 7,500 | 108 | 810,000 | D |
09 Jan 2023 18:21 | NVCR | NovoCure Ltd | LEONARD FRANK X | President, CNS Cancers US | 05 Jan 2023 | Sale | 7,826 | 108 | 845,208 | D |
09 Jan 2023 18:21 | NVCR | NovoCure Ltd | LEONARD FRANK X | President, CNS Cancers US | 05 Jan 2023 | Sale | 1,010 | 117 | 118,170 | D |
09 Jan 2023 18:21 | NVCR | NovoCure Ltd | LEONARD FRANK X | President, CNS Cancers US | 05 Jan 2023 | Sale | 526 | 115.0348 | 60,508 | D |
09 Jan 2023 18:21 | NVCR | NovoCure Ltd | LEONARD FRANK X | President, CNS Cancers US | 05 Jan 2023 | Sale | 417 | 108 | 45,036 | D |
09 Jan 2023 18:21 | NVCR | NovoCure Ltd | LEONARD FRANK X | President, CNS Cancers US | 05 Jan 2023 | Sale | 2,345 | 119.0077 | 279,073 | D |
09 Jan 2023 18:20 | NVCR | NovoCure Ltd | SHAH PRITESH | Chief Commercial Officer | 05 Jan 2023 | Sale | 387 | 108 | 41,796 | D |
09 Jan 2023 18:18 | NVCR | NovoCure Ltd | DANZIGER ASAF | Chief Executive Officer | 05 Jan 2023 | Sale | 187,500 | 108 | 20,250,000 | D |
09 Jan 2023 18:18 | NVCR | NovoCure Ltd | DANZIGER ASAF | Chief Executive Officer | 05 Jan 2023 | Sale | 500 | 119.987 | 59,994 | D |
09 Jan 2023 18:18 | NVCR | NovoCure Ltd | DANZIGER ASAF | Chief Executive Officer | 05 Jan 2023 | Sale | 1,344 | 119.3493 | 160,405 | D |
09 Jan 2023 18:18 | NVCR | NovoCure Ltd | DANZIGER ASAF | Chief Executive Officer | 05 Jan 2023 | Sale | 2,123 | 118.4714 | 251,515 | D |
09 Jan 2023 18:18 | NVCR | NovoCure Ltd | DANZIGER ASAF | Chief Executive Officer | 05 Jan 2023 | Sale | 999 | 117.0111 | 116,894 | D |
09 Jan 2023 18:18 | NVCR | NovoCure Ltd | DANZIGER ASAF | Chief Executive Officer | 05 Jan 2023 | Sale | 1,395 | 116.0618 | 161,906 | D |
09 Jan 2023 18:18 | NVCR | NovoCure Ltd | DANZIGER ASAF | Chief Executive Officer | 05 Jan 2023 | Sale | 3,702 | 115.2113 | 426,512 | D |
09 Jan 2023 18:18 | NVCR | NovoCure Ltd | DANZIGER ASAF | Chief Executive Officer | 05 Jan 2023 | Sale | 4,568 | 114.3524 | 522,362 | D |
09 Jan 2023 18:18 | NVCR | NovoCure Ltd | DANZIGER ASAF | Chief Executive Officer | 05 Jan 2023 | Sale | 2,000 | 112.8632 | 225,726 | D |
09 Jan 2023 18:18 | NVCR | NovoCure Ltd | DANZIGER ASAF | Chief Executive Officer | 05 Jan 2023 | Sale | 8,369 | 111.2338 | 930,916 | D |
17 Oct 2022 16:35 | NVCR | NovoCure Ltd | LEONARD FRANK X | President, CNS Cancers US | 13 Oct 2022 | Sale | 6,754 | 76.01 | 513,372 | D |
07 Oct 2022 16:16 | NVCR | NovoCure Ltd | LEONARD FRANK X | President, CNS Cancers US | 06 Oct 2022 | Sale | 6,754 | 84.37 | 569,835 | D |
30 Sep 2022 16:20 | NVCR | NovoCure Ltd | LEONARD FRANK X | President, CNS Cancers US | 29 Sep 2022 | Sale | 6,754 | 77.35 | 522,422 | D |
26 Sep 2022 16:19 | NVCR | NovoCure Ltd | LEONARD FRANK X | President, CNS Cancers US | 22 Sep 2022 | Sale | 6,754 | 77 | 520,058 | D |
* D/I = Direct / Indirect
* 10% = Entity with 10% or higher ownership stake
* A = Amendment Filing (SEC Form 4/A)